Validation of a Digital Pathology–Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy
The MMAI biomarker, previously shown to be prognostic for distant metastasis and prostate cancer-specific mortality in men receiving definitive radiation, was prognostic for post-RP endpoints: BCR and AP. This biomarker validation study further supports the use of MMAI biomarkers in men with prostate cancer outside North America and those treated with RP.
Authors
- Anders Bjartell (ORCID: https://orcid.org/0000-0002-5761-3786)
- Felix Yi-Chung Feng (ORCID: https://orcid.org/0000-0002-0963-7687)
- Meghan Tierney (ORCID: https://orcid.org/0000-0003-4918-2370)
- Marisol Macarena Palominos-Rivera
- Emmalyn Chen (ORCID: https://orcid.org/0000-0002-4179-5773)
- Agnieszka Krzyzanowska (ORCID: https://orcid.org/0000-0002-1288-7054)
- Martin Sjöström (ORCID: https://orcid.org/0000-0002-2629-9966)
- Trevor J. Royce (ORCID: https://orcid.org/0000-0001-9879-1290)
- Andre Esteva (ORCID: https://orcid.org/0000-0003-1937-9682)
- Vinnie Y.T. Liu (ORCID: https://orcid.org/0000-0002-7152-6830)
- Alexandra Kraft (ORCID: https://orcid.org/0000-0001-8020-0712)
Institutions
- University of California, San Francisco (US)
- Lund University (SE)
- Skåne University Hospital (SE)
- Alto Neuroscience (United States) (US)
- University of San Francisco (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3656
- Citations
- 7
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 8.16